| Ann Thomas, MD | |
|
8415 N Pima Rd, Ste 150, Scottsdale, AZ 85258-0000 | |
| (480) 551-1057 | |
| (480) 551-1059 |
| Full Name | Ann Thomas |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 35 Years |
| Location | 8415 N Pima Rd, Scottsdale, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821061607 | NPI | - | NPPES |
| 517443 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 27537 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Scottsdale Dialysis (fmc) | Scottsdale, AZ | Dialysis facility |
| Desert Mountain Dialysis (dva) | Scottsdale, AZ | Dialysis facility |
| Honorhealth Scottsdale Shea Medical Center | Scottsdale, AZ | Hospital |
| Scottsdale Thompson Peak Medical Center | Scottsdale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Akdhc Llc | 8123912136 | 124 |
News Archive
Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
Yongye International, Inc.("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), today announced its financial results for the fourth quarter and full year ended December 31, 2013.
Allergies occur when the defence mechanisms of the immune system malfunction and misread normal substances entering the body as invading pathogens. Antibodies are part of our biochemical arsenal for combating viruses, bacteria, parasites and other alien substances, but during an allergic reaction the antibody, known as IgE, is directed against usually harmless substances such as grass pollen, nuts, pets or eggs. However, researchers from COPSAC (Copenhagen Studies on Asthma in Childhood) at the Faculty of Health Sciences, University of Copenhagen recently discovered indications that IgE in the blood of the umbilical cord could originate from the mother, and decided to conduct a focused study on this.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
› Verified 7 days ago
| Entity Name | Akdhc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316902208 PECOS PAC ID: 8123912136 Enrollment ID: O20040211000250 |
News Archive
Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
Yongye International, Inc.("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), today announced its financial results for the fourth quarter and full year ended December 31, 2013.
Allergies occur when the defence mechanisms of the immune system malfunction and misread normal substances entering the body as invading pathogens. Antibodies are part of our biochemical arsenal for combating viruses, bacteria, parasites and other alien substances, but during an allergic reaction the antibody, known as IgE, is directed against usually harmless substances such as grass pollen, nuts, pets or eggs. However, researchers from COPSAC (Copenhagen Studies on Asthma in Childhood) at the Faculty of Health Sciences, University of Copenhagen recently discovered indications that IgE in the blood of the umbilical cord could originate from the mother, and decided to conduct a focused study on this.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ann Thomas, MD 6622 N 91st Ave, Ste 220, Glendale, AZ 85305-2569 Ph: (602) 759-6883 | Ann Thomas, MD 8415 N Pima Rd, Ste 150, Scottsdale, AZ 85258-0000 Ph: (480) 551-1057 |
News Archive
Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
Yongye International, Inc.("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), today announced its financial results for the fourth quarter and full year ended December 31, 2013.
Allergies occur when the defence mechanisms of the immune system malfunction and misread normal substances entering the body as invading pathogens. Antibodies are part of our biochemical arsenal for combating viruses, bacteria, parasites and other alien substances, but during an allergic reaction the antibody, known as IgE, is directed against usually harmless substances such as grass pollen, nuts, pets or eggs. However, researchers from COPSAC (Copenhagen Studies on Asthma in Childhood) at the Faculty of Health Sciences, University of Copenhagen recently discovered indications that IgE in the blood of the umbilical cord could originate from the mother, and decided to conduct a focused study on this.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
› Verified 7 days ago
Russell S Ruzich, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Paul Joseph Schenk, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 11230 E Beck Ln, Scottsdale, AZ 85255 Phone: 480-502-9457 | |
Dr. Musab Sultan Hommos, M.B., B.S. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Soyoung Park, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 10460 N 92nd St Ste 300, Scottsdale, AZ 85258 Phone: 480-323-1573 Fax: 480-323-1375 | |
Dr. Michael Edward Killian, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: Mayo Clinic 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 085-120-6856 | |
Hesham Mubarak Ibrahim Moh Abdalla, M.B.B.S. Nephrology Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Kianoush Cheybani, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 9590 E Ironwood Square Dr, Ste 125, Scottsdale, AZ 85258 Phone: 480-455-3000 Fax: 866-819-6115 |